NICE draft guidance refuses pembrolizumab plus axitinib combination

The National Institute for Health and Care Excellence (NICE) have issued an interim decision not to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Appraisal Consultation Document (ACD) released this week, NICE stated that there was uncertainty about the long-term […]

read more

Lenvatinib plus pembrolizumab shows promise in solid tumours

The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%). The combination was […]

read more

Sarcomatoid RCC – molecular features and new opportunities for treatment

Sarcomatoid renal cell carcinoma (RCC) is difficult to treat and has long been associated with a poor prognosis. Also, the biology of sarcomatoid RCC has remained obscure. Scientists have tried to determine the molecular profile of sarcomatoid RCC and investigate different targeted therapies for genes such as TP53, BAP1, cell cycle, and chromatin-remodelling genes. Investigation of […]

read more

The future of immunotherapy-based combinations for metastatic kidney cancer

The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]

read more

Immunotherapy combinations standard of care for advanced kidney cancer

In 2015, the standard treatment for most patients with advanced kidney cancer was a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) such as sunitinib or pazopanib for untreated patients, followed by a checkpoint inhibitor (PD-1 inhibitor) such as nivolumab for patients who fail treatment with a VEGF inhibitor. However, over the last several […]

read more

Individualised treatment plans improve outcomes for kidney cancer

Over the past couple of years there have been several approvals of new treatments and drug combinations for advanced/metastatic renal cell carcinoma (RCC) resulting in treatment plans that are tailored for the individual patient. Recent advances in the treatment of advanced/metastatic RCC include cabozantinib, nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib. Dr Ajjai Shivaram Alva, associate professor at […]

read more

Predictive biomarkers needed for combination treatments in kidney cancer

In this interview with OncLive, Dr Ulka Vaishampayan from Wayne State University in Detroit, USA discusses the immunotherapy combinations that have been approved for first line treatment of metastatic renal cell carcinoma (mRCC) over the past year or so, and the need to identify biomarkers that can guide treatment selection for these patients. The combination […]

read more

PARP inhibitors, vaccines and combination therapies for kidney cancer

In this interview with OncLive, professor Sumanta Kumar Pal from City of Hope Hospital in California discusses the potential of poly ADP ribose polymerase (PARP) inhibitors, chimeric antigen receptor (CAR)-based products, vaccines, and novel drug combinations for the treatment of metastatic renal cell carcinoma (mRCC). Results from the phase Ib/II TiNivo study of the combination […]

read more

Major updates in the management of metastatic kidney cancer

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center in Houston, Texas, talks about the introduction of immunotherapy and immunotherapy-targeted therapy combinations over the past two years for the first-line treatment of metastatic renal cell carcinoma (RCC). Watch the video interview on Practice Update here

read more

Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less […]

read more
Showing 1 to 10 of 64 results
  TOP